Visit https://www.peervoice.com/NAK860 to view the entire programme with slides. After completing “Modern Management of Chronic Kidney Disease: A Look to the Future”, participants will be able to: Explain the rationale for novel therapies for the management of chronic kidney disease (CKD); Evaluate the safety and efficacy of recent clinical data for managing CKD, focusing on novel therapies; and Analyse the clinical implications of emerging evidence for managing CKD.

Visit https://www.peervoice.com/EQD860 to view the entire programme with slides. After completing “Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies”, participants will be able to: Evaluate recent clinical data for current first-line treatment options in patients with advanced EGFR-mutant NSCLC, within the context of long-term care; Discuss strategies and options for managing specific challenges that can impact first-line treatment selection in patients with advanced EGFR-mutant NSCLC; and Formulate optimal treatment strategies that maximise outcomes in patients with advanced EGFR-mutant NSCLC.

Visit https://www.peervoice.com/VGT860 to view the entire programme with slides. After completing “Breaking the Cycle of Severe Hypoglycemia in Diabetes: Educating Clinicians and Patients Alike”, participants will be able to: Identify patients at risk of severe hypoglycemia; Evaluate the benefits and limitations of current pharmacologic strategies for the management of severe hypoglycemia; and Formulate approaches for educating patients and their caregivers about severe hypoglycemia and early and appropriate treatment.

Visit https://www.peervoice.com/TWQ860 to view the entire programme with slides. After completing “Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data”, participants will be able to: Explain the rationale for targeted therapy in early-stage EGFR-mutant NSCLC; Assess recent clinical data for EGFR tyrosine kinase inhibitors (TKIs) as adjuvant therapy for patients with early-stage EGFR-mutant NSCLC; and Describe how EGFR TKIs may impact the treatment paradigm for early-stage EGFR-mutant NSCLC.

Visit https://www.peervoice.com/CPA860 to view the entire programme with slides. After completing “Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?”, participants will be able to: Evaluate recent survival data associated with androgen receptor (AR)-targeted therapies in patients with nmCRPC; Discuss why quality of life (QoL) should be prioritised when managing patients with nmCRPC; and Propose treatment plans for patients with nmCRPC that optimally balance efficacy with QoL, with a focus on adverse events.

Visit https://www.peervoice.com/PEB860 to view the entire programme with slides. After completing “Practical Approaches to Optimise Management of Advanced Renal Cell Carcinoma”, participants will be able to: Outline an approach to maximise efficacy while managing toxicity associated with tyrosine kinase inhibitors (TKI) in patients with advanced renal cell carcinoma (RCC); Describe best practices for implementing this approach in clinical practice; and Identify areas to optimise management of patients on TKIs.

Visit https://www.peervoice.com/XEF860 to view the entire programme with slides. After completing “Defining Control in Moderate-to-Severe Asthma: Where Are We Now and What Can We Do?”, participants will be able to: Recognise limitations regarding current concepts of asthma control; Understand the role of biomarkers in the treatment of moderate-to-severe asthma; and Develop targeted strategies for assessing and managing moderate-to-severe asthma.

Visit https://www.peervoice.com/AJN860 to view the entire programme with slides. After completing “Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy”, participants will be able to: Characterise the incidence and impact of colchicine resistance among patients with FMF; Understand disease burden from the perspective of the patient; and Analyse the long-term clinical and quality-of-life (QoL) data for anti–IL-1 therapy in colchicine-resistant FMF.

Visit https://www.peervoice.com/ATJ860 to view the entire programme with slides. After completing “Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist”, participants will be able to: Discuss the rationale for MET biomarker testing in patients with non–small-cell lung cancer (NSCLC); Describe current testing modalities for patients with NSCLC and recent advances in identifying novel mutations; and Apply MET biomarker testing as standard of care for patients with NSCLC.

Visit https://www.peervoice.com/QHW860 to view the entire programme with slides. After completing “Tailor-Made: How Precision Medicine Is Shaping Cancer Care”, participants will be able to: Discuss the rationale behind precision medicine and the growing importance of targeting genomic alterations; and Illustrate the clinical implications of personalized cancer care and the need to find the right treatment for the right patient.